Assembly Biosciences’ (ASMB) “Buy” Rating Reiterated at William Blair

William Blair reissued their buy rating on shares of Assembly Biosciences (NASDAQ:ASMB) in a research note released on Tuesday morning, AnalystRatings.com reports.

A number of other equities analysts also recently weighed in on ASMB. Zacks Investment Research downgraded shares of ExlService from a hold rating to a sell rating in a report on Wednesday, July 10th. Chardan Capital restated a hold rating on shares of Assembly Biosciences in a report on Sunday, June 30th. Finally, BidaskClub downgraded shares of Walgreens Boots Alliance from a sell rating to a strong sell rating in a report on Monday, June 24th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and four have given a buy rating to the company’s stock. The stock has an average rating of Hold and a consensus price target of $41.20.

NASDAQ ASMB opened at $13.97 on Tuesday. The company has a quick ratio of 7.97, a current ratio of 7.97 and a debt-to-equity ratio of 0.06. Assembly Biosciences has a 12-month low of $12.75 and a 12-month high of $44.65. The firm has a market capitalization of $358.21 million, a P/E ratio of -3.51 and a beta of 1.46. The firm has a 50 day simple moving average of $14.14.

Assembly Biosciences (NASDAQ:ASMB) last posted its quarterly earnings data on Thursday, May 9th. The biopharmaceutical company reported ($1.05) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($1.06) by $0.01. The company had revenue of $3.89 million for the quarter, compared to the consensus estimate of $3.81 million. Assembly Biosciences had a negative net margin of 671.48% and a negative return on equity of 56.45%. On average, sell-side analysts predict that Assembly Biosciences will post -4.34 earnings per share for the current fiscal year.

A number of hedge funds have recently added to or reduced their stakes in ASMB. Deutsche Bank AG boosted its position in shares of Assembly Biosciences by 29.8% in the fourth quarter. Deutsche Bank AG now owns 54,606 shares of the biopharmaceutical company’s stock valued at $1,234,000 after acquiring an additional 12,525 shares during the period. New York State Common Retirement Fund boosted its position in shares of Assembly Biosciences by 15.3% in the fourth quarter. New York State Common Retirement Fund now owns 23,300 shares of the biopharmaceutical company’s stock valued at $527,000 after acquiring an additional 3,100 shares during the period. Tibra Equities Europe Ltd bought a new stake in shares of Assembly Biosciences in the first quarter valued at about $918,000. Emerald Mutual Fund Advisers Trust boosted its position in shares of Assembly Biosciences by 13.3% in the first quarter. Emerald Mutual Fund Advisers Trust now owns 418,143 shares of the biopharmaceutical company’s stock valued at $8,233,000 after acquiring an additional 49,230 shares during the period. Finally, FMR LLC boosted its position in shares of Assembly Biosciences by 136.0% in the fourth quarter. FMR LLC now owns 443,036 shares of the biopharmaceutical company’s stock valued at $10,021,000 after acquiring an additional 255,336 shares during the period. 86.44% of the stock is owned by hedge funds and other institutional investors.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc operates as a clinical-stage biotechnology company in the United States. The company develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome.

Further Reading: The Discount Rate – What You Need to Know

Analyst Recommendations for Assembly Biosciences (NASDAQ:ASMB)

Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.